INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 13, Issue 5- 2026

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2026.13.05.004

Circulatory Disturbances of the Liver: Pathophysiology, Clinical Features, and Management

***Emmanuel Ifeanyi Obeagu[1, 2] and Queen Braxton N. Anaebo[3]**

[1]Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.
[2]The Division of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
[3]R. Jolad Hospital, Isolo, Lagos, Lagos State, Nigeria.
*Corresponding author: Emmanuel IfeanyiObeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, emmanuelobeagu@yahoo.com,
ORCID: 0000-0002-4538-0161

Abstract

Circulatory disturbances of the liver encompass a diverse group of vascular disorders that profoundly affect hepatic function and systemic health. These disturbances arise from complex interactions involving the liver's unique dual blood supply and can result from a variety of systemic or localized conditions such as heart failure, portal vein thrombosis, or hepatic venous outflow obstruction. The spectrum includes hepatic congestion, ischemic hepatitis, portal hypertension, and Budd-Chiari syndrome, each characterized by distinct pathophysiological mechanisms that disrupt normal liver perfusion and architecture. Clinically, these disorders present with a wide range of manifestations, from subtle biochemical abnormalities to acute liver failure and life-threatening complications such as variceal hemorrhage and ascites. Early recognition remains challenging due to overlapping symptoms with other hepatic diseases, emphasizing the critical role of advanced diagnostic modalities including Doppler ultrasonography,

CT, MRI, and invasive hemodynamic assessments. Management strategies are evolving with a focus on treating the root causes, alleviating portal hypertension, and preventing progression to irreversible liver damage. Therapeutic approaches range from medical optimization of cardiac and systemic conditions to interventional radiology procedures like transjugular intrahepatic portosystemic shunting and, in severe cases, liver transplantation. Advances in imaging and minimally invasive treatments offer promising prospects for improved outcomes, underscoring the importance of a multidisciplinary approach to these complex vascular liver disorders.

Keywords: Hepatic Circulatory Disturbances, Portal Hypertension, Hepatic Congestion, Budd-Chiari Syndrome, Ischemic Hepatitis

Introduction

The liver, one of the most vascular organs in the body, plays a critical role in metabolism, detoxification, synthesis of vital proteins, and regulation of hemodynamics. Uniquely, it receives a dual blood supply: approximately 75% from the portal vein and 25% from the hepatic artery. This distinctive vascular architecture not only supports its diverse physiological functions but also renders it highly susceptible to a variety of circulatory disturbances. Any disruption in hepatic blood flow—whether from systemic, cardiac, or local vascular causes—can precipitate significant hepatic dysfunction and systemic consequences [1-2].Circulatory disturbances of the liver encompass a spectrum of disorders, including hepatic congestion, ischemic hepatitis, portal hypertension, and hepatic vascular thrombosis. These conditions may arise independently or as secondary complications of systemic diseases such as heart failure, sepsis, or coagulopathies. In many cases, the underlying circulatory abnormality precedes overt liver disease, making early identification and management crucial for preventing irreversible hepatic damage [3-4].

Hepatic congestion, for instance, is most commonly associated with right-sided heart failure or constrictive pericarditis. It leads to a backward transmission of pressure to the hepatic veins and sinusoids, resulting in sinusoidal dilation, hypoxia, and eventually centrilobular necrosis—a condition often termed “cardiac cirrhosis.” Conversely, ischemic hepatitis, or “shock liver,” occurs due to a sudden reduction in hepatic perfusion, typically in the context of hypotension or severe hypoxemia. The result is rapid hepatocellular injury, characterized by a striking elevation in serum aminotransferases [5].Another critical circulatory disturbance is portal hypertension, a pathologic increase in portal venous pressure, most often secondary to chronic liver diseases such as cirrhosis. However, non-cirrhotic causes such as schistosomiasis, portal vein thrombosis, and idiopathic portal hypertension also play a role. The clinical consequences—splenomegaly, ascites, hepatic encephalopathy, and variceal bleeding—represent major sources of morbidity and mortality, particularly in resource-limited settings [6].Equally significant are vascular occlusive disorders such as Budd-Chiari syndrome (hepatic vein thrombosis) and portal vein thrombosis. These conditions obstruct venous outflow or inflow to the liver, disrupting hepatic microcirculation and leading to hepatomegaly, pain, ascites, and progressive liver failure. Inherited thrombophilias, malignancy, myeloproliferative neoplasms, and oral contraceptive use are among the common predisposing factors [7].

Pathophysiology

The liver’s distinctive vascular architecture—receiving approximately 75% of its blood supply from the portal vein and 25% from the hepatic artery—renders it particularly sensitive to changes in systemic and local circulatory dynamics. Any disruption to this intricate balance can result in profound hepatocellular injury and architectural remodeling [8].Hepaticcongestion arises primarily from elevated central venous pressure, typically due to right-sided heart failure or constrictive pericarditis. This increased back pressure leads to

sinusoidal dilatation, hepatocyte atrophy in the centrilobular zones, and ultimately perivenular fibrosis, a hallmark of cardiac cirrhosis. Prolonged congestion can result in hypoxic injury and architectural distortion of the hepatic lobules [9].Ischemichepatitis, also known as "shock liver," occurs in the setting of systemic hypotension or acute circulatory collapse, where reduced hepatic arterial inflow leads to widespread hepatocyte necrosis, particularly in the centrilobular regions. Despite the liver's dual blood supply, a significant drop in perfusion pressure can compromise oxygen delivery, especially in watershed zones vulnerable to ischemia [10].

Portalhypertension represents a hemodynamic consequence of increased resistance to portal blood flow, either pre-hepatic (e.g., portal vein thrombosis), intrahepatic (e.g., cirrhosis, schistosomiasis), or post-hepatic (e.g., Budd-Chiari syndrome). The elevated portal venous pressure induces the formation of portosystemic collateral channels, varices, and splenomegaly, and contributes to complications such as ascites and hepatic encephalopathy [11].Vascular thromboses further disrupt hepatic circulation. Portal vein thrombosis can lead to reduced hepatopetal flow, compromising nutrient and toxin clearance. In contrast, hepatic vein thrombosis, as seen in Budd-Chiari syndrome, causes outflow obstruction, leading to hepatic congestion, increased sinusoidal pressure, hepatocyte necrosis, and progressive fibrosis [12]. These vascular disturbances not only impair hepatic metabolic and synthetic function but can also drive the progression to fibrosis and cirrhosis. The liver's capacity for regeneration can partially compensate for transient insults, but chronic or severe circulatory derangements can culminate in irreversible structural damage and liver failure (Table 1).

Table 1: Pathophysiology of Major Circulatory Disturbances of the Liver

Condition	Primary Hemodynamic Disturbance	Key Pathophysiologic Mechanisms	Resulting Hepatic Changes
Congestive Hepatopathy	Passive venous congestion due to elevated right atrial/central venous pressure	Sinusoidal dilation; stasis of blood; chronic hypoxia; mechanical stretch of hepatocytes	Centrilobular fibrosis; "nutmeg liver"; progression to cardiac cirrhosis
Budd–Chiari Syndrome	Obstruction of hepatic venous outflow at hepatic veins/IVC	Increased sinusoidal pressure; hepatocellular necrosis; collateral vessel formation; hepatic ischemia	Hepatomegaly; ascites; centrilobular necrosis; regenerative nodules
Portal Vein Thrombosis	Reduced portal venous inflow	Thrombotic occlusion; compensatory arterial hyperperfusion; splanchnic congestion	Portal hypertension; cavernous transformation; preserved hepatocyte function unless ischemic injury occurs
Sinusoidal Obstruction Syndrome (SOS/VOD)	Microvascular obstruction of sinusoids and terminal hepatic venules	Endothelial cell injury; sloughing and subendothelial edema; deposition of fibrin and cellular debris	Sinusoidal collapse; painful hepatomegaly; centrilobular congestion; acute portal hypertension
Ischemic Hepatitis (Shock Liver)	Acute reduction in hepatic arterial and portal perfusion	Severe hypoxia; ATP depletion; oxidative stress; rapid hepatocyte death	Massive centrilobular necrosis; extreme elevations of AST/ALT; usually reversible if perfusion restored

Clinical Presentation

The clinical manifestations of circulatory disturbances of the liver are diverse, reflecting the complexity of hepatic vascular anatomy and the systemic conditions that often underlie these disorders. Symptoms may range from subtle, asymptomatic laboratory abnormalities to dramatic presentations of acute liver failure, making early recognition a diagnostic challenge [13].Hepatic congestion, typically secondary to right-sided heart failure or constrictive pericarditis, often presents insidiously. Patients may report vague right upper quadrant discomfort, fatigue, and abdominal distention due to hepatomegaly and ascites. On examination, elevated jugular venous pressure and peripheral edema may be evident, and laboratory tests may reveal mild elevations in transaminases and bilirubin [14].Ischemic hepatitis, also known as "shock liver," presents acutely with a rapid, transient rise in aminotransferase levels—often exceeding 1000 IU/L—following an episode of systemic hypotension, sepsis, or cardiogenic shock. Clinical symptoms are often overshadowed by the primary illness, but severe hepatic hypoperfusion can lead to hepatic encephalopathy and coagulopathy if left unrecognized [14].

Portal hypertension, a hallmark of chronic hepatic circulatory disruption, manifests with classic signs such as splenomegaly, ascites, and portosystemic collateral formation. Patients are at risk of life-threatening complications including esophageal or gastric variceal bleeding. Early symptoms may include abdominal fullness, early satiety, and fatigue [15].Budd-Chiari syndrome, caused by hepatic venous outflow obstruction, may present in acute, subacute, or chronic forms. Acute presentations include severe abdominal pain, hepatomegaly, ascites, and sometimes jaundice. Chronic cases may mimic cirrhosis with features of portal hypertension, while fulminant presentations can rapidly progress to liver failure [16].Because circulatory disturbances often occur in the setting of other systemic or hepatic diseases, a high index of clinical suspicion, coupled with appropriate diagnostic imaging, is crucial for timely intervention and prevention of irreversible liver damage [17].

Diagnostic Modalities

Accurate and timely diagnosis of circulatory disturbances of the liver requires a multimodal approach integrating clinical suspicion, laboratory findings, and advanced imaging techniques. Given the nonspecific nature of many hepatic symptoms and the overlap with other liver pathologies, careful selection and interpretation of diagnostic tools are essential for delineating the underlying vascular disturbance [18].Laboratory investigations provide initial clues. Hepatic congestion and ischemic hepatitis often manifest with a marked elevation in aminotransferases—particularly aspartate aminotransferase (AST) and alanine aminotransferase (ALT)—while cholestatic patterns may be observed in cases involving portal hypertension or hepatic venous outflow obstruction. Elevated bilirubin, prolonged prothrombin time, and hypoalbuminemia indicate impaired hepatic synthetic function and signal disease progression. In suspected thrombotic conditions, coagulation profiles and thrombophilia screening (including protein C, protein S, antithrombin III levels, and antiphospholipid antibodies) are useful adjuncts [19].

Ultrasound with Doppler is the cornerstone of noninvasive vascular imaging. It allows real-time assessment of hepatic blood flow, detection of portal vein thrombosis, reversal of portal flow (hepatofugal flow), and visualization of hepatic vein obstruction. Doppler sonography is particularly valuable for evaluating the patency of the portal and hepatic veins and for detecting collateral vessel formation [20].Cross-sectional imaging, including contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI), offers superior anatomical detail and functional insights. CT angiography can detect thrombi, varices, ascites, and collateral circulation. MRI with MR angiography provides high-resolution images of hepatic vessels and is particularly sensitive in diagnosing Budd-Chiari syndrome and chronic portal vein thrombosis.

Dynamic contrast studies can highlight perfusion abnormalities, delineate hepatic congestion patterns, and differentiate between acute and chronic changes [21].In complex or inconclusive cases, hepaticvenographymay be used to directly visualize venous outflow obstruction, particularly in Budd-Chiari syndrome, and guide interventional procedures. Liverbiopsy, though used sparingly, remains a valuable tool when histopathological confirmation is needed—particularly to differentiate congestive hepatopathy from other causes of liver dysfunction. Findings such as centrilobular necrosis, sinusoidal dilation, and fibrosis provide diagnostic clarity in challenging cases [22].

Management Strategies

Effective management of circulatory disturbances of the liver hinges on early recognition, targeted intervention, and a multidisciplinary approach tailored to the underlying etiology. As these vascular disorders often stem from systemic or extrahepatic pathology, addressing the root cause is as crucial as managing hepatic complications [23].Hepatic congestion, primarily due to right-sided heart failure or constrictive pericarditis, necessitates optimized cardiac function. Diuretics are commonly used to alleviate venous congestion, while afterload reduction and management of underlying cardiac conditions can significantly reverse hepatic derangements. In refractory cases, pericardiectomy or advanced heart failure therapies may be indicated [24].Ischemic hepatitis demands prompt hemodynamic stabilization. Management focuses on correcting the precipitating cause—such as shock, hypoxia, or arrhythmia—through fluid resuscitation, inotropic support, or mechanical ventilation. As liver injury is often transient, supportive care and close monitoring of hepatic function are generally sufficient unless multiorgan failure ensues [25].

Portal hypertension management is aimed at preventing complications such as variceal bleeding and ascites. Non-selective beta-blockers (e.g., propranolol, nadolol) are first-line agents to reduce portal pressure. Endoscopic interventions, including variceal band ligation, are crucial for acute and secondary prophylaxis of bleeding. In patients with refractory portal hypertension, transjugular intrahepatic portosystemic shunt (TIPS) provides an effective decompressive solution, though it carries risks such as hepatic encephalopathy [26].Hepatic vein thrombosis (Budd-Chiari syndrome) and portal vein thrombosis require prompt anticoagulation to restore flow and prevent progression. Low-molecular-weight heparin followed by oral anticoagulants is the standard of care. In severe cases with progressive liver dysfunction or failed medical therapy, interventions such as thrombolysis, angioplasty, or TIPS may be considered. Surgical shunting or liver transplantation is reserved for end-stage disease or fulminant presentations [27].Across all subtypes, nutritional support, monitoring for complications such as ascites and encephalopathy, and routineimaging are integral to ongoing care. Liver transplantation remains the ultimate option for patients with irreversible hepatic failure or complications unresponsive to medical and interventional therapy [28-19].

Conclusion

Circulatory disturbances of the liver encompass a diverse array of vascular abnormalities that profoundly influence hepatic structure and function. These conditions, ranging from hepatic congestion and ischemic hepatitis to portal hypertension and hepatic vascular thrombosis, reflect the intricate relationship between hepatic hemodynamics and systemic physiology. Despite their varied etiologies, these disturbances share a common pathway of vascular compromise leading to hepatocellular injury, fibrosis, and, in advanced cases, liver failure. Timely diagnosis, guided by a thorough clinical evaluation and advanced imaging modalities, is critical to preventing irreversible hepatic damage. Equally important is a tailored therapeutic approach that addresses both the hepatic consequences and the underlying systemic drivers, such as cardiac dysfunction, thrombophilic states, or chronic liver disease. The emergence of minimally invasive interventions, such as TIPS and endovascular therapies, has

transformed the management landscape, offering effective options for patients previously considered untreatable.

Conflicts of Interest

The author declares no conflict of interest

Sources of Funding

No fund was received to write this review paper

Ethical Approval

Not applicable

Consent

Not applicable

Abbreviations

AASLD – American Association for the Study of Liver Diseases
ALT – Alanine Aminotransferase
APASL – Asian Pacific Association for the Study of the Liver
AST – Aspartate Aminotransferase
BCS – Budd–Chiari Syndrome
CT – Computed Tomography
DUS – Doppler Ultrasonography
EASL – European Association for the Study of the Liver
HVPG – Hepatic Venous Pressure Gradient
IVC – Inferior Vena Cava
LFTs – Liver Function Tests
MRI – Magnetic Resonance Imaging
PVT – Portal Vein Thrombosis
SOS – Sinusoidal Obstruction Syndrome
TIPS – Transjugular Intrahepatic Portosystemic Shunt
VOD – Veno-Occlusive Disease

References

1. Lautt WW. Hepatic Circulation: Physiology and Pathophysiology. San Rafael (CA): Morgan & Claypool Life Sciences; 2009.
2. Lorente S, Hautefeuille M, Sanchez-Cedillo A. The liver, a functionalized vascular structure. Sci Rep. 2020;10(1):16194. doi: 10.1038/s41598-020-73208-8.
3. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol. 2011;20(3):135-142. doi: 10.1055/s-0031-1284434.
4. DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49(5):1729-64. doi: 10.1002/hep.22772.
5. Fortea JI, Puente Á, Cuadrado A, Huelin P, Pellón R, González Sánchez FJ, Mayorga M, Cagigal ML, García Carrera I, Cobreros M, Crespo J, Fábrega E. Congestive Hepatopathy. Int J Mol Sci. 2020;21(24):9420. doi: 10.3390/ijms21249420.
6. Kibrit J, Khan R, Jung BH, Koppe S. Clinical Assessment and Management of Portal Hypertension. SeminInterventRadiol. 2018;35(3):153-159. doi: 10.1055/s-0038-1660793.
7. DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49(5):172917-64. doi: 10.1002/hep.22772.
8. Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol. 2010;16(48):6046-6057. doi: 10.3748/wjg. v16.i48.6046.
9. Hilscher M, Sanchez W. Congestive hepatopathy. Clin Liver Dis (Hoboken). 2016;8(3):68-71. doi: 10.1002/cld.573.

10. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol. 2011;20(3):135-142. doi: 10.1055/s-0031-1284434.
11. Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep. 2021;3(4):100316. doi: 10.1016/j.jhepr.2021.100316.
12. Valla DC. Hepatic vein thrombosis and PVT: A personal view on the contemporary development of ideas. Clin Liver Dis (Hoboken). 2024;23(1): e0246. doi: 10.1097/CLD.0000000000000246.
13. Liu P, Liang WL, Huang RT, Chen XX, Zou DH, Kurihara H, Li YF, Xu YH, Ouyang SH, He RR. Hepatic microcirculatory disturbance in liver diseases: intervention with traditional Chinese medicine. Front Pharmacol. 2024; 15:1399598. doi: 10.3389/fphar.2024.1399598.
14. Bezjak M, Kocman B, Jadrijević S, Gašparović H, Mrzljak A, Kanižaj TF, Vujanić D, Bubalo T, Mikulić D. Constrictive pericarditis as a cause of refractory ascites after liver transplantation: A case report. World J Clin Cases. 2019;7(20):3266-3270. doi: 10.12998/wjcc. v7.i20.3266.
15. Dib N, Oberti F, Calès P. Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ. 2006 May 9;174(10):1433-43. doi: 10.1503/cmaj.051700.
16. Jang JW, Yoon SK, Bae SH, Choi JY, Chung KW, Sun HS. Rapidly progressing Budd-Chiari syndrome complicated by hepatocellular carcinoma. Korean J Intern Med. 2003;18(3):191-5. doi: 10.3904/kjim.2003.18.3.191.
17. DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49(5):1729-64. doi: 10.1002/hep.22772.
18. Sah AK, Afzal M, Elshaikh RH, Abbas AM, Shalabi MG, Prabhakar PK, Babker AMA, Khalimova FT, Sabrievna VA, Choudhary RK. Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes. Life (Basel). 2025;15(5):779. doi: 10.3390/life15050779.
19. Ciobanu AO, Gherasim L. Ischemic Hepatitis - Intercorrelated Pathology. Maedica (Bucur). 2018;13(1):5-11.
20. Maruyama H, Yokosuka O. Ultrasonography for Noninvasive Assessment of Portal Hypertension. Gut Liver. 2017;11(4):464-473. doi: 10.5009/gnl16078.
21. Silickas J, Black SA, Phinikaridou A, Gwozdz AM, Smith A, Saha P. Use of Computed Tomography and Magnetic Resonance Imaging in Central Venous Disease. Methodist DebakeyCardiovasc J. 2018;14(3):188-195. doi: 10.14797/mdcj-14-3-188.
22. Song RX, Cai SF, Ma S, Liu ZL, Gai YH, Zhang CQ, Wang GC. Magnetic Resonance Venography Findings of Obstructed Hepatic Veins and the Inferior Vena Cava in Patients with Budd-Chiari Syndrome. Korean J Radiol. 2018;19(3):381-388. doi: 10.3348/kjr.2018.19.3.381.
23. Zhang YR, Wang H, Zhou N, Zhang YD, Lin Y, Wu LY, Wei SF, Ma YY, Wang CX. A Multidisciplinary Team Approach to the Treatment of Liver Cirrhosis. J Inflamm Res. 2021; 14:5443-5450. doi: 10.2147/JIR.S328334.
24. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol. 2011;20(3):135-142. doi: 10.1055/s-0031-1284434.
25. Guo G, Wu XZ, Su LJ, Yang CQ. Clinical features of ischemic hepatitis caused by shock with four different types: a retrospective study of 328 cases. Int J Clin Exp Med. 2015;8(9):16670-5.
26. Elfeki MA, Singal AK, Kamath PS. Pharmacotherapies for Portal Hypertension: Current Status and Expanding Indications. CurrHepatol Rep. 2023r;22(1):44-50. doi: 10.1007/s11901-023-00600-z.
27. Malakar S, Mathur A, Agarwal A, Mishra P, Shirol VV, Yadav RR, Ghoshal UC. Budd Chiari Syndrome with Portal Vein Thrombosis Managed Successfully with Direct Intrahepatic Portosystemic Shunt: A Case Report and Review of the Literature. J

ClinExpHepatol. 2023;13(5):917-920. doi: 10.1016/j.jceh.2023.06.005.
28. Anastácio LR, Davisson Correia MI. Nutrition therapy: Integral part of liver transplant care. World J Gastroenterol. 2016;22(4):1513-22. doi: 10.3748/wjg.v22.i4.1513.

Access this Article in Online	
Quick Response Code	Website: www.ijcrcps.com Subject: Pathophysiology
DOI: 10.22192/ijcrcps.2026.13.05.004	

How to cite this article:
Emmanuel Ifeanyi Obeagu and Queen Braxton N. Anaebo. (2026). Circulatory Disturbances of the Liver: Pathophysiology, Clinical Features, and Management. Int. J. Curr. Res. Chem. Pharm. Sci. 13(5): 33-40.
DOI: http://dx.doi.org/10.22192/ijcrcps.2026.13.05.004

